A risk-benefit assessment of naltrexone in the treatment of alcohol dependence

Drug Safety

Volumn 15, Issue 4, 1996, Pages 274-282

  Berg, Bruce J ^a   Pettinati, Helen M ^a   Volpicelli, Joseph R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTITUSSIVE AGENT; MORPHINE DERIVATIVE; NALTREXONE; OPIATE; PHENYTOIN; THIORIDAZINE;

ALCOHOLISM; DEPRESSION; DRINKING BEHAVIOR; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DYSPHORIA; HUMAN; LIVER TOXICITY; MENTAL DISEASE; MOOD; NAUSEA; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; VOMITING;

EID: 0029958271     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615040-00005     Document Type: Review

References (44)

1. Volpicelli JR, O'Brien CP, Arthur AI, et al. Naltrexone and the treatment of alcohol-dependence: initial observations. In: Reid LD, editor. Opioids, bulimia, and alcohol abuse & alcoholism. New York: Springer-Verlag, 1990
2. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80
3. O'Malley SS, Jaffe AJ, Chang O, et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49: 881-7
4. Ulm RR, Volpicelli JR, Volpicelli LA. Opiates und alcohol self-administration in animals. J Clin Psychiatry 1995; 56 (7 Suppl.): 5-14
5. Froehlich JC. Genetic factors in alcohol self-administration. J Clin Psychiatry 1995; 56 (7 Suppl.): 15-23
6. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol 'high' in alcoholics. Am J Psychiatry 1995; 152 (4): 613-5
7. Volpicelli JR. Uncontrollable events and alcohol drinking. Br J Addict 1987; 82 (4): 381-92
8. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiatry Neurosci 1993; 18 (4): 148-56
9. Data on file, DuPont Merck
10. Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obesity 1985; 9: 347-53
11. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985; 38 (4): 419-22
12. Mitchell JE, Morley JE, Levine AS, et al. High dose naltrexone and dietary counselling for obesity. Biol Psychiatry 1987; 22: 35-42
13. Marrazzi MA, Markham KM, Kinzie J, et al. Binge eating disorder: response to naltrexone. Int J Obesity 1995; 19 (2); 143-5
14. Pfohl DN, Allen JI, Atkinson RL, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. In: Harris LS, editor. Problems on drug dependence. Proceedings of the 47th Annual Scientific Meeting of the Committee on Problems of Alcohol Dependence, 1985 Jun 8-13. Rockville: The Committee on Problems of Drug Dependence, Inc, National Institute on Drug Abuse, Office of Science, 1986; 66-72 (National Institute on Drug Abuse Research Monograph; 67)
15. Gillberg C. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 1995; 37 (3): 239-45
16. Benjamin S, Seek A, Tresise L, et al. Case study: paradoxical response to naltrexone treatment of sell-injurious behavior. J Am Acad Child Adolesc Psychiatry 1995 Feb; 34 (2): 238-42
17. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52 (9): 766-73
18. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA 1986; 256 (11): 1449-55
19. Ohara H, Miyabe Y, Deyashiki Y, et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995; 50 (2): 221-7
20. Verebey K, Volavka J, Mule SJ, et al. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976; 20 (3): 315-28
21. Dayton HE, Inturrisi CE. The urinary excretion profiles of naltrexone in man, monkey, rabbit and rat. Drug Metab Dispos 1976; 4: 474-8
22. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213
23. Verebey K, Mule SJ. Naltrexone and β-naltrexol plasma levels in schizophrenic patients. Res Commun Psychol Psychiatry Behav 1979; 4 (3): 311-7
24. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996
25. Kleber HD, Kosten TR, Gaspari J, et al. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 1985; 20: 66-72
26. Kosten TR, Kreek MJ, Ragunath J, et al. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 1986; 21: 217-20
27. Volavka J, Mallya A, Bauman J, et al. Hormonal and other effects of naltrexone in normal men. Adv Exp Med Biol 1979; 116: 291-305
28. Kosten TR, Kreek MJ, Ragunath J, et al. A preliminary study of β-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 1986; 39: 55-9
29. Mendelson JH, Ellingboe J, Keuhnle JC, et al. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1978; 3: 231-6
30. Mendelson JH, Ellingboe J, Kuehnle JC, et al. Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther 1980; 214: 503-6
31. Mendelson JH, Mello NK, Cristofaro P, et al. Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function. Pharmacol Biochem Behav 1986; 24: 309-13
32. Mirin SM, Mendelson JH, Ellingboe J, et al. Acute effects of heroin and naltrexone on testosterone and gonadotropin secretion: a pilot study. Psychoneuroendocrinology 1976; 1: 359-69
33. Ellingboe J, Mendelson JH, Kuehnle JC. Effects of heroin and naltrexone on plasma prolactin levels in man. Pharmacol Biochem Behav 1980; 12: 163-5
34. Wildt L, Leyendecker G. Induction of ovulation by the chronic administration of naltrexone in hypothalamic amenorrhea. J Clin Endocrinol Metab 1987; 64 (6): 1334-5
35. Keshet GI, Weinstock M. Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress. Pharmacol Biochem Behav 1995; 50 (3): 413-9
36. Maestroni G, Conti A, Pierpaoli W. Role of the pineal gland in immunity: II. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol 1987; 68: 384-91
37. Crowley TJ, Wagner JE, Zerbe G, et al. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 1985; 142 (9): 1081-4
38. Brahen LS, Capone TJ, Capone DM. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol 1988; 28: 64-70
39. Greenstein RA, Resnick RB, Resnick E. Methadone and naltrexone in the treatment of heroin dependence. Psychiatr Clin North Am 1984; 7 (4): 671-9
40. Lee MC, Wagner HN, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29 (7): 1207-11
41. Maany I, O'Brien CP, Woody G. Interaction between thioridazine and naltrexone [letter]. Am J Psychiatry 1987; 144 (7): 966
42. Gilmore R, Hack R, Kuhn R, et al. Naltrexone-associated decrease in phenytoin concentration [letter]. Epilepsia 1989; 3 (5): 738
43. Marrazzi MA, Jacober S, Luby ED. A naltrexone-induced increase in insulin requirement. J Clin Psychopharmacol 1994; 14 (5); 363-5
44. Physicians' Desk Reference, 50th ed. Montvale (NJ): Medical Economics Co., 1996